Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT07174388
Official study title

An External Control Arm Study in Non-Small Cell Lung Cancer

Study summary

A study to create control arms using current and future information in patients with lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 22, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?11 U.S. locations

Locations may change over time.

Who runs it?N-Power Medicine

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
N-Power Medicine
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. \> 18 years of age at the time of informed consent 2. Pathologically confirmed locally advanced or metastatic NSCLC 3. ECOG Performance of less than or equal to 1 within 4 weeks prior to starting index therapy. 4. Life expectancy of more than 3 months 5. Able to understand and sign informed consent 6. Evidence of measurable disease (as assessed by the Investigator) on available imaging (e.g CT, MRI, PET) \*see protocol for cohort specific inclusion criteria\

Reasons someone may not be able to joinExclusion criteria

1. Actively on a clinical trial of an investigational agent 2. Currently receiving active systemic therapy for another malignancy 3. Eligible for treatment with curative intent \*see protocol for cohort specific

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Pacific Cancer CareMonterey, California
  • Bayhealth Medical Center, Kent CampusDover, Delaware
  • Bayhealth Medical Center- Sussex CampusMilford, Delaware
  • Northwest Oncology and HematologyBarrington, Illinois
  • Northwest Oncology and HematologyElk Grove, Illinois
  • Northwest Oncology and HematologyHoffman Estates, Illinois
  • Northwest Oncology and HematologyRolling Meadows, Illinois
  • New Mexico Oncology Hematology ConsultantsAlbuquerque, New Mexico
  • New York Cancer and Blood SpecialistsNew York, New York
  • Main Line HealthWynnewood, Pennsylvania
  • Oncology ConsultantsHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 22, 2026. Always confirm current availability with the study team.

View original record ↗